Kenneth G Cornetta, Joe C. Christian Professor And Chair
Indiana Univ-purdue Univ At Indianapolis 620 Union Drive, Room 618 Indianapolis, In 462025167
Grant 5P01HL053586-139002 from National Heart, Lung, And Blood Institute IRG: HLBP
Project start date: 2007-07-01
Project end date: 2010-06-30
Sponsored Links Excellgen http://Excellgen.com
Kenneth G Cornetta, Joe C. Christian Professor And Chair
Indiana Univ-purdue Univ At Indianapolis 620 Union Drive, Room 618 Indianapolis, In 462025167
Grant 5P01HL053586-109002 from National Heart, Lung, And Blood Institute
Abstract: A shared vector production facility is proposed which will supply clinical grade viral vector for the projects participating in this program. The core will also supply FDA and RAC required safety testing for patients participating in clinical gene therapy trials. A facility capable of producing and testing retroviral and adeno-associated viral vectors will be housed in the Cancer Research Building and will occupy 1800 sq. feet of space. The laboratory is specifically designed for the production of clinical grade viral vector under Good Laboratory and Good Manufacturing Practice criteria. Clinical grade supernate will be produced by a technician with experience in GMP production and a technician with experience in retroviral vector testing. The facility will be overseen by an investigator who has successfully written Investigational New Drug (IND) applications for retroviral vectors and is currently conducting clinical trials using retroviral vectors. The laboratory will play a critical role in bringing the viral vectors developed in this project to clinical trial.
Keywords: biomedical facility, biotechnology, transfection /expression vector, Lentivirus, Retroviridae, cell line, genetic transduction, germ free condition, microorganism growth, polymerase chain reaction
Project start date: 2004-02-29
Project end date: 2005-02-28
Kenneth G Cornetta, Joe C. Christian Professor And Chair
Indiana Univ-purdue Univ At Indianapolis 620 Union Drive, Room 618 Indianapolis, In 462025167
Grant 5P01HL053586-099002 from National Heart, Lung, And Blood Institute
Abstract: A shared vector production facility is proposed which will supply clinical grade viral vector for the projects participating in this program. The core will also supply FDA and RAC required safety testing for patients participating in clinical gene therapy trials. A facility capable of producing and testing retroviral and adeno-associated viral vectors will be housed in the Cancer Research Building and will occupy 1800 sq. feet of space. The laboratory is specifically designed for the production of clinical grade viral vector under Good Laboratory and Good Manufacturing Practice criteria. Clinical grade supernate will be produced by a technician with experience in GMP production and a technician with experience in retroviral vector testing. The facility will be overseen by an investigator who has successfully written Investigational New Drug (IND) applications for retroviral vectors and is currently conducting clinical trials using retroviral vectors. The laboratory will play a critical role in bringing the viral vectors developed in this project to clinical trial.
Keywords: biomedical facility, biotechnology, transfection /expression vector, Lentivirus, Retroviridae, cell line, genetic transduction, germ free condition, microorganism growth, polymerase chain reaction
Kenneth G Cornetta, Joe C. Christian Professor And Chair
Indiana Univ-purdue Univ At Indianapolis 620 Union Drive, Room 618 Indianapolis, In 462025167
Grant 5P01HL053586-129002 from National Heart, Lung, And Blood Institute IRG: HLBP
Project start date: 2006-07-01
Project end date: 2010-06-30
Grants awarded to Kenneth G Cornetta
NATIONAL GENE VECTOR BIORESPOSITORY AND COORDINATING CENTER AT INDIANA UNIVERSIT
Kenneth G Cornetta, Joe C. Christian Professor & Chairman
Indiana Univ-purdue Univ At Indianapolis, 620 Union Drive, Room 518, Indianapolis, In 46202-5167
Abstract: This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To enable researchers at the National Gene Vector Biorespository to have access to the most current technology
Keywords: CRISP; Computer Retrieval of Information on Scientific Projects Database; Funding; Genes; Grant; Indiana; Institution; Investigators; NIH; National Institutes of Health; National Institutes of Health (U.S.); Research; Research Personnel; Research Resources; Researchers; Resources; Source; Technology; United States National Institutes of Health; Universities; vector
Project start date: 2009-08-13
Project end date: 2011-08-12
Budget start date: 13-AUG-2009
Budget end date: 12-AUG-2011
PFA/PA: RFA-RR-07-002
3P40RR024928-02S1_8265 (2009): $249620
Kenneth G Cornetta, Joe C. Christian Professor And Chair
Indiana Univ-purdue Univ At Indianapolis 620 Union Drive, Room 618 Indianapolis, In 462025167
Grant 5P30DK049218-099002 from National Institute Of Diabetes And Digestive And Kidney Diseases
Abstract: The Vector Cores is designed to facilitate gene therapy research and was established during the first funding period. This shared facility has allowed consolidated of resources and promoted interactions among thje gene therapy investigators at IU. During the initial funding period, the Vector Core sought to facilitate basic retroviral gene therapy research by supplying certified packaging of cell lines and supernate. The components of the Vector Core are (1) A production laboratory capable of generating retroviral vectors using certified packaging cell lines. Funds are requested to support generation of packaging cell lines for basic science efforts of the CCEMH, including production of retroviral and lentiviral material. CCEMH funds are not requested to support the clinical production efforts of the Vector Core; (2) a Vector Testing Laboratory which can assay packaging cell lines or other material used by CCEMH investigators to insure they are pathogen free; and (3) a Molecular Diagnostic Laboratory which provides CCEMH investigators to insure they are pathogen free; and (3) a Molecular Diagnostic Laboratory which provides CCEMH investigators with rapid vector determinations and estimation of gene transfer using quantitative PCR. In addition, the laboratory is skilled at assessing gene transfer into hematopoietic progenitors using PCR of individual progenitor colonies. The Molecular Diagnostic Laboratory is also involved with sample processing for clinical gene therapy samples. For the upcoming funding period, the core will (1) provide investigators with high titer retroviral and lentiviral packaging cell lines, (2) provide molecular diagnostic services, including quantitative PCR, and (3) provide consistent handling of clinical samples from patients participating in gene therapy trials and provide safety testing of clinical samples as mandated by the FDA.
Keywords: biomedical facility, hematology, transfection /expression vector, biological product, cell line, polymerase chain reaction, Retroviridae, human tissue